insulin glulisine vs Insulin Lispro
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline
insulin glulisine · Apidra
Marketed by Sanofi
NCT00290927 · Phase 3 · completed
The trial randomized 390 participants but was not blinded; the registry describes comparisons with oral diabetes therapy. Its primary efficacy endpoint was change in HbA1c, a surrogate measure, and because no results are posted, it is not possible to determine whether the primary comparison was met.
Reported efficacy
Compare the change in glycemic control (as measured by A1c) from baseline to endpoint of fixed dose bolus regimen vs. variable bolus regimen based on carbohydrate count: Primary endpoint (A1C change from baseline to week 24, noninferiority of carbohydrate-counting vs a simple fixed-dose algorithm for mealtime insulin glulisine, both arms on insulin glargine as basal): simple algorithm -1.46%, carb count -1.59%; difference -0.13% (95% CI -0.35 to 0.09%), within the pre-specified 0.5% noninferiority margin. Enrollment (281 randomized) matches this NCT exactly. (met)
Result source: NCT00135057
Insulin Lispro · Humalog
Marketed by Eli Lilly
NCT01474538 · Phase 3 · completed
The study randomized 122 participants to receive both insulin lispro and insulin aspart in crossover order, with participants, investigators, and outcome assessors masked. Its primary clinical endpoint, HbA1c after 16 weeks, met the prespecified non-inferiority criterion for lispro versus aspart, with the upper confidence limit below the 0.4% margin.
Next expected readout: December 2026 · NCT06251635 (registry estimate)
Reported efficacy
Glycosylated Hemoglobin A1C (HbA1c) at Endpoint (After 16 weeks of each treatment (Periods1 and 2)): Glycosylated Hemoglobin A1C (HbA1c) at Endpoint (After 16 weeks of each treatment (Periods1 and 2)): Insulin Lispro 7.5 percentage of glycosylated hemoglobin (Standard Error 0.12) | Insulin Aspart 7.4 percentage of glycosylated hemoglobin (Standard Error 0.12) (met)
Result source: NCT01474538
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | insulin glulisine | Insulin Lispro |
|---|---|---|
| HbA1c, change | -0.5% vs -0.5%vs Insulin LisproNCT011942582 other results
| -1.2% vs -1.1%vs Insulin GlargineNCT0162117820 other results
|
| Body weight, change (kg) | 0.5 vs 0.2vs Insulin Glargine+Metformin+GlimepirideNCT003606981 other result
| -2.8 vs 1.1vs Insulin GlargineNCT0162117815 other results
|
| HbA1c below 7% | 22.4% vs 8.8%vs Insulin Glargine+Metformin+GlimepirideNCT003606981 other result
| 32.9% vs 29.1%vs Insulin GlargineNCT016211783 other results
|
| Fasting plasma glucose, change | —Not posted · NCT00135057 | -2.0 vs -1.5vs Insulin Lispro + Insulin GlargineNCT022292274 other results
|
| 3-point MACE (% with event) | —Not posted · NCT00135057 | —Not posted · NCT00551356 |
HbA1c, change
- insulin glulisine
- -0.5% vs -0.5%vs Insulin LisproNCT01194258
2 other results
- -0.4% vs -0.1% NCT00360698
- -2.5% vs -2.1% NCT00384085
- Insulin Lispro
- -1.2% vs -1.1%vs Insulin GlargineNCT01621178
20 other results
- -1.6% vs -1.4% NCT01191268
- -1.1% vs -1.1% NCT01621178
- -1.6% vs -1.4% NCT01191268
- -1.2% vs -1.3% NCT00666718
- -1.0% vs -1% NCT05462756
- -1.0% vs -1.1% NCT02229227
- -1.7% vs -1.4% NCT01468987
- -1.5% vs -1.2% NCT01191268
- -1.4% vs -1.2% NCT01191268
- -1.1% vs -1.3% NCT00666718
- -1.0% vs -1% NCT05462756
- -1.0% vs -1.1% NCT02229227
- -1.0% vs -1.1% NCT02229227
- -0.9% vs -1.0% NCT00666718
- -0.9% vs -1.0% NCT02229227
- -0.7% vs -0.6% NCT02229227
- -0.6% vs -0.5% NCT02229227
- -1.1% vs -1% NCT01621178
- -1.1% vs -1% NCT01621178
- -1% vs -0.8% NCT00393705
Body weight, change (kg)
- insulin glulisine
- 0.5 vs 0.2vs Insulin Glargine+Metformin+GlimepirideNCT00360698
1 other result
- 1.5 vs 1.6 NCT01194258
- Insulin Lispro
- -2.8 vs 1.1vs Insulin GlargineNCT01621178
15 other results
- -2.0 vs 1.1 NCT01621178
- -1.7 vs 1.6 NCT01621178
- 1.0 vs 1.2 NCT00666718
- 2.7 vs 2.5 NCT05462756
- -1.9 vs 2.4 NCT02229227
- -1.9 vs 2.4 NCT02229227
- 1.3 vs 2.2 NCT01468987
- -2.0 vs 2.1 NCT02229227
- -1.7 vs 1.5 NCT02229227
- -0.9 vs 0.8 NCT02229227
- -0.6 vs 0.7 NCT02229227
- -2.7 vs 1.6 NCT01621178
- 0.3 vs 0.9 NCT01474538
- 1.3 vs 0.4 NCT00393705
- 2.6 vs 2.7 NCT00664534
HbA1c below 7%
- insulin glulisine
- 22.4% vs 8.8%vs Insulin Glargine+Metformin+GlimepirideNCT00360698
1 other result
- 51.1% vs 39.5% NCT00384085
- Insulin Lispro
- 32.9% vs 29.1%vs Insulin GlargineNCT01621178
3 other results
- 37.5% vs 34.6% NCT01621178
- 33.5% vs 29.1% NCT01621178
- 31.7% vs 34.6% NCT01621178
Fasting plasma glucose, change
- insulin glulisine
- —Not posted · NCT00135057
- Insulin Lispro
- -2.0 vs -1.5vs Insulin Lispro + Insulin GlargineNCT02229227
4 other results
- -2.0 vs -1.5 NCT02229227
- -1.8 vs -1.2 NCT02229227
- -1.1 vs -0.9 NCT02229227
- -1.3 vs -0.8 NCT02229227
3-point MACE (% with event)
- insulin glulisine
- —Not posted · NCT00135057
- Insulin Lispro
- —Not posted · NCT00551356
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety
Coverage. insulin glulisine: 6 of 6 rows · Insulin Lispro: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | insulin glulisine Rows use multiple source trials | Insulin Lispro Rows use multiple source trials |
|---|---|---|
| HbA1c absolute value · percentage points | 7.5% (n=49) vs 7.8% (n=57) Insulin Glargine+Metformin+Glimepiride @ 24wka,b,c NCT00360698 · Phase 4 · registry result, not featured evidence · combination | 7.4% (n=108) vs 7.55% (n=98) Glargine @ 48wkd,a,b,c NCT00664534 · Phase 4 · registry result, not featured evidence show 1 more dose7.33% (n=158) vs 7.4% (n=163) Glargine @ 48wk NCT00664534 · Phase 4 · registry result, not featured evidence |
| HbA1c Less Than 7% responder rate · % of participants HbA1c < 7.0% | 43.3% (n=187) vs 38.6% (n=189) Novolog Mix 70/30 @ 60wkd,e,a,b,f NCT00384085 · Phase 4 · registry result, not featured evidence · combination show 1 more dose44.1% (n=195) vs 38.1% (n=197) Novolog Mix 70/30 @ 60wk NCT00384085 · Phase 4 · registry result, not featured evidence · combination | 36% (n=179) vs 50% (n=180) Glargine @ 24wke,a,b,f HbA1c < 7.0% NCT00666718 · Phase 3 · registry result, not featured evidence |
| Dropout rate | 23.5%Lantus/Apidra-1g NCT00384085 · Phase 4 · registry result, not featured evidence · combination show 4 more results20%Lantus/Apidra-3 NCT00384085 · Phase 4 · registry result, not featured evidence · combination — NCT00360698 · Phase 4 · registry result, not featured evidence · combination —Aspart-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence —Lispro-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence | —h NCT01474538 · Phase 3 show 18 more results19.3% NCT00664534 · Phase 4 · registry result, not featured evidence 15.2% NCT00393705 · Phase 4 · registry result, not featured evidence · combination 4.7% NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 12.7% NCT02229227 · Phase 3 · registry result, not featured evidence · combination —1.5 mg NCT01621178 · Phase 3 · registry result, not featured evidence —0.75 mg NCT01621178 · Phase 3 · registry result, not featured evidence 10.3% NCT01468987 · Phase 3 · registry result, not featured evidence · combination 19.7%1.5 mg NCT01191268 · Phase 3 · registry result, not featured evidence 18.8%0.75 mg NCT01191268 · Phase 3 · registry result, not featured evidence —Glargine/Lispro NCT00666718 · Phase 3 · registry result, not featured evidence · combination 9.6%ILPS NCT00666718 · Phase 3 · registry result, not featured evidence —Lispro/Metformin NCT00666718 · Phase 3 · registry result, not featured evidence · combination —Insulin Lispro (Lispro-PH20 Cohort NCT01194258 · Phase 2 · registry result, not featured evidence —Lispro-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence —Humalog + rHuPH20 NCT00916357 · Phase 2 · registry result, not featured evidence · combination —Humalog Alone NCT00916357 · Phase 2 · registry result, not featured evidence · monotherapy — NCT02197520 · Phase 1 · registry result, not featured evidence 11.1% NCT05893797 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | 2.6%Lantus/Apidra-1g NCT00384085 · Phase 4 · registry result, not featured evidence · combination show 4 more results2.6%Lantus/Apidra-3 NCT00384085 · Phase 4 · registry result, not featured evidence · combination — NCT00360698 · Phase 4 · registry result, not featured evidence · combination —Aspart-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence —Lispro-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence | —h NCT01474538 · Phase 3 show 18 more results1.8% NCT00664534 · Phase 4 · registry result, not featured evidence 0% NCT00393705 · Phase 4 · registry result, not featured evidence · combination 0.8% NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 3.5% NCT02229227 · Phase 3 · registry result, not featured evidence · combination —1.5 mg NCT01621178 · Phase 3 · registry result, not featured evidence —0.75 mg NCT01621178 · Phase 3 · registry result, not featured evidence 1.7% NCT01468987 · Phase 3 · registry result, not featured evidence · combination 7.1%1.5 mg NCT01191268 · Phase 3 · registry result, not featured evidence 4.4%0.75 mg NCT01191268 · Phase 3 · registry result, not featured evidence —Glargine/Lispro NCT00666718 · Phase 3 · registry result, not featured evidence · combination 0.5%ILPS NCT00666718 · Phase 3 · registry result, not featured evidence —Lispro/Metformin NCT00666718 · Phase 3 · registry result, not featured evidence · combination —Insulin Lispro (Lispro-PH20 Cohort NCT01194258 · Phase 2 · registry result, not featured evidence —Lispro-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence —Humalog + rHuPH20 NCT00916357 · Phase 2 · registry result, not featured evidence · combination —Humalog Alone NCT00916357 · Phase 2 · registry result, not featured evidence · monotherapy — NCT02197520 · Phase 1 · registry result, not featured evidence 2.8% NCT05893797 · Phase na · registry result, not featured evidence |
| Serious AEs | 11.9%Lantus/Apidra-1g NCT00384085 · Phase 4 · registry result, not featured evidence · combination show 4 more results11.3%Lantus/Apidra-3 NCT00384085 · Phase 4 · registry result, not featured evidence · combination 2% NCT00360698 · Phase 4 · registry result, not featured evidence · combination 6.5%Aspart-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence 0%Lispro-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence | 12.7%h NCT01474538 · Phase 3 show 18 more results4.1% NCT00664534 · Phase 4 · registry result, not featured evidence 2.2% NCT00393705 · Phase 4 · registry result, not featured evidence · combination 6.8% NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 5.8% NCT02229227 · Phase 3 · registry result, not featured evidence · combination 21.4%1.5 mg NCT01621178 · Phase 3 · registry result, not featured evidence 25.3%0.75 mg NCT01621178 · Phase 3 · registry result, not featured evidence 11.4% NCT01468987 · Phase 3 · registry result, not featured evidence · combination 9.2%1.5 mg NCT01191268 · Phase 3 · registry result, not featured evidence 15.7%0.75 mg NCT01191268 · Phase 3 · registry result, not featured evidence 4.8%Glargine/Lispro NCT00666718 · Phase 3 · registry result, not featured evidence · combination —ILPS NCT00666718 · Phase 3 · registry result, not featured evidence 7.5%Lispro/Metformin NCT00666718 · Phase 3 · registry result, not featured evidence · combination 0%Insulin Lispro (Lispro-PH20 Cohort NCT01194258 · Phase 2 · registry result, not featured evidence 0%Lispro-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence 4.5%Humalog + rHuPH20 NCT00916357 · Phase 2 · registry result, not featured evidence · combination 0%Humalog Alone NCT00916357 · Phase 2 · registry result, not featured evidence · monotherapy 0% NCT02197520 · Phase 1 · registry result, not featured evidence 8.3% NCT05893797 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | g any infections and infestations 42.3% any musculoskeletal and connective tissue disorders 22.7% any gastrointestinal disorders 16.5% NCT00384085 · Phase 4 · registry result, not featured evidence · combination show 3 more resultsany infections and infestations 34% any musculoskeletal and connective tissue disorders 23.2% any nervous system disorders 20.1% NCT00384085 · Phase 4 · registry result, not featured evidence · combination uterine leiomyoma 6.7% arthralgia 6.5% headache 6.5% NCT01194258 · Phase 2 · registry result, not featured evidence upper respiratory tract infection 11.9% diarrhoea 8.5% nasopharyngitis 5.1% NCT01194258 · Phase 2 · registry result, not featured evidence | show 17 more resultspyrexia 3.6% neuropathy peripheral 3% diarrhoea 2.4% NCT00664534 · Phase 4 · registry result, not featured evidence nasopharyngitis 4.3% bronchitis 2.2% arthralgia 1.4% NCT00393705 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 6.3% influenza 3.8% NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 nausea 9.3% diarrhoea 7.8% viral upper respiratory tract infection 6.3% NCT02229227 · Phase 3 · registry result, not featured evidence · combination 1.5 mg blood creatinine increased 38.5% nausea 19.8% diarrhoea 16.1% NCT01621178 · Phase 3 · registry result, not featured evidence 0.75 mg blood creatinine increased 37.4% diarrhoea 15.8% nausea 14.2% NCT01621178 · Phase 3 · registry result, not featured evidence nasopharyngitis 7.1% upper respiratory tract infection 4.2% diarrhoea 3.5% NCT01468987 · Phase 3 · registry result, not featured evidence · combination 1.5 mg nausea 25.8% diarrhea 14.9% vomiting 11.9% NCT01191268 · Phase 3 · registry result, not featured evidence 0.75 mg nausea 17.7% diarrhea 11.6% vomiting 10.6% NCT01191268 · Phase 3 · registry result, not featured evidence nasopharyngitis 6.4% headache 5.9% diarrhoea 4.3% NCT00666718 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 5.3% headache 4.8% viral infection 3.7% NCT00666718 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 6.8% headache 3.4% influenza 3.4% NCT01194258 · Phase 2 · registry result, not featured evidence upper respiratory tract infection 11.9% diarrhoea 8.5% nasopharyngitis 5.1% NCT01194258 · Phase 2 · registry result, not featured evidence abdominal pain 4.5% diarrhoea 4.5% injection site pain 4.5% NCT00916357 · Phase 2 · registry result, not featured evidence · combination headache 13.6% nausea 9.1% abdominal pain 4.5% NCT00916357 · Phase 2 · registry result, not featured evidence · monotherapy catheter site related reaction 12.5% upper respiratory tract infection 12.5% urinary tract infection 12.5% NCT02197520 · Phase 1 · registry result, not featured evidence covid-19 8.3% bronchitis 5.6% dermatitis allergic 5.6% NCT05893797 · Phase na · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cAssessment timepoints differ: 48 weeks versus 24 weeks.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- eTrial phases differ: Phase 3 versus Phase 4.
- fAssessment timepoints differ: 24 weeks versus 60 weeks.
- gPopulation comparability has not been reviewed for these studies.
- hPopulation comparability has not been reviewed for 18 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
insulin glulisine
show 1 more result
Insulin Lispro
show 1 more result
+ 45 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin glulisine's landscape · Insulin Lispro's landscape